Literature DB >> 21296329

Risk factors for the development and progression of carcinoid heart disease.

Sanjeev Bhattacharyya1, Christos Toumpanakis, Deepika Chilkunda, Martyn Evan Caplin, Joseph Davar.   

Abstract

The development of valvular heart disease in patients with carcinoid syndrome is thought to be related to the secretion of vasoactive substances by a tumor. We sought to identify modifiable risk factors for the development of carcinoid heart disease because this may help define strategies to attenuate the disease process. Two hundred fifty-two patients with carcinoid syndrome were prospectively followed with serial echocardiograms at 6-month intervals. Clinical characteristics, biochemical markers, and radiologic markers were measured at set intervals. An echocardiographic scoring system was applied. Patients were defined as having progression of carcinoid heart disease if the echocardiographic score increased by ≥25%. After a median follow-up of 29 months, 44 patients developed carcinoid heart disease or had progression of existing valvular dysfunction. At time of progression of carcinoid heart disease compared to the previous 6 months, there was a significant increase in median levels of 5-hydroxyindoleacetic acid (5-HIAA; 791 vs 460.5 μmol/24 hours) and flushing episodes (4.5 vs 2 episodes per day). Independent predictors of the development or progression of carcinoid heart disease were a 5-HIAA level ≥ 300 μmol/24 hours and ≥ 3 episodes of flushing per day. 5-HIAA levels of ≥ 300 to 599, 600 to 899, and > 900 μmol/24 hours conferred 2.74, 3.16, and 3.40 times the risk of progression of carcinoid heart disease, respectively. In conclusion, a 5-HIAA level ≥ 300 μmol/24 hours and ≥ 3 flushing episodes per day are predictors of the development or progression of carcinoid heart disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296329     DOI: 10.1016/j.amjcard.2010.12.025

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

Review 1.  Carcinoid Heart Disease: Review of Current Knowledge.

Authors:  Pradhum Ram; Jorge L Penalver; Kevin Bryan U Lo; Janani Rangaswami; Gregg S Pressman
Journal:  Tex Heart Inst J       Date:  2019-02-01

Review 2.  Ileal neuroendocrine tumors and heart: not only valvular consequences.

Authors:  Jan Calissendorff; Eva Maret; Anders Sundin; Henrik Falhammar
Journal:  Endocrine       Date:  2014-10-16       Impact factor: 3.633

Review 3.  Carcinoid-syndrome: recent advances, current status and controversies.

Authors:  Tetsuhide Ito; Lingaku Lee; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-02       Impact factor: 3.243

Review 4.  The use of biomarkers in neuroendocrine tumours.

Authors:  Mohid Shakil Khan; Martyn E Caplin
Journal:  Frontline Gastroenterol       Date:  2013-03-21

Review 5.  Cardiothoracic manifestations of neuroendocrine tumours.

Authors:  Ramin Mandegaran; Sarojini David; Nicholas Screaton
Journal:  Br J Radiol       Date:  2016-01-19       Impact factor: 3.039

Review 6.  Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy.

Authors:  Evan D Lehrman; Nicholas Fidelman
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

7.  Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.

Authors:  Camilla Schalin-Jäntti; Niina Matikainen; Iiro Kostiainen; Noora Karppinen; Piia Simonen; Milla Rosengård-Bärlund; Riikka Lindén; Maija Tarkkanen; Daniel Gordin; Janne Rapola
Journal:  Endocrine       Date:  2022-05-10       Impact factor: 3.925

8.  Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Authors:  Marianne E Pavel; Alexandria T Phan; Edward M Wolin; Beloo Mirakhur; Nilani Liyanage; Susan Pitman Lowenthal; George A Fisher; Aaron I Vinik
Journal:  Oncologist       Date:  2018-10-24

9.  Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach.

Authors:  Ashlie Nadler; Moises Cukier; Laurent Milot; Simron Singh; Calvin H Law
Journal:  Can J Surg       Date:  2014-04       Impact factor: 2.089

Review 10.  Update in carcinoid heart disease - the heart of the matter.

Authors:  Kira Oleinikov; Amit Korach; David Planer; Dan Gilon; Simona Grozinsky-Glasberg
Journal:  Rev Endocr Metab Disord       Date:  2021-01-14       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.